Dosage & Administration Efficacy safety testing Drug label Prior authorization Financial assistance

Jakafi

(ruxolitinib)

ruxolitinib 10 MG Oral Tablet [Jakafi]ruxolitinib 15 MG Oral Tablet [Jakafi]

View 3 more

NO BLACK BOX WARNING

Dosage & administration

Doses should be individualized based on safety and efficacy. Starting doses per indication are noted below.

Myelofibrosis

* The starting dose of Jakafi is based on patient’s baseline platelet count:
            •  Greater than 200 x 109/L: 20 mg given orally twice daily
            •  100 x 109/L to 200 x 109/L: 15 mg given orally twice daily
            •  50 x 109/L to less than 100 x 109/L: 5 mg given orally twice daily
* Monitor complete blood counts every 2 to 4 weeks until doses are stabilized, and then as clinically indicated. Modify or interrupt dosing for thrombocytopenia.

Polycythemia Vera

* The starting dose of Jakafi is 10 mg given orally twice daily.

Acute Graft-Versus-Host Disease

The starting dose of Jakafi is 5 mg given orally twice daily.

Chronic Graft-Versus-Host Disease

* The starting dose of Jakafi is 10 mg given orally twice daily.

eficacy, safety & testing

Jakafi clinical details

Mechanism of Action (MOA): Polycythemia Vera (PV)

Efficacy: Polycythemia Vera (PV)

Safety Profile: Polycythemia Vera (PV)

Dosing: Polycythemia Vera (PV)

Mechanism of Action (MOA): Myelofibrosis (MF)

Efficacy: Myelofibrosis (MF)

Safety Profile: Myelofibrosis (MF)

Dosing: Myelofibrosis (MF)

Mechanism of Action (MOA): Acute GVHD

Efficacy: Acute GVHD

Safety Profile: Acute GVHD

Dosing: Acute GVHD

Mechanism of Action (MOA): Chronic GVHD

Efficacy: Chronic GVHD

Safety Profile: Chronic GVHD

Dosing: Chronic GVHD

drug label

Jakafi prescribing information

Have more Jakafi questions?

Submit MSL Request

Learn More

Need to report a Jakafi issue?

ONLINE FORMReport adverse event

Learn More

prior authorization

Jakafi Prior authorization resources

Complete Letter of Medical Necessity

NOT PROVIDED BY BRANDCoverage Authorization Request

Coverage Authorization Appeals

Learn More

Benefits investigation

IncyteCARES for Jakafi Program Enrollment Form

Patient Authorization for the IncyteCARES for Jakafi Program - Online

IncyteCARES for Jakafi Program Enrollment Form - Online

Learn More

Reimbursement help (FRM)

Receive Assistance from an FRM Regarding Reimbursement Information

Learn More

financial assistance

Jakafi Financial assistance options

Co-pay savings program

commercial only

IncyteCARES for Jakafi Program Enrollment Form

Patient Authorization for the IncyteCARES for Jakafi Program - Online

IncyteCARES for Jakafi Program Enrollment Form - Online

Enroll in Patient Savings Program - HCP Office

Enroll in Patient Savings Program - Patient

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Bridge program

commercial only

IncyteCARES for Jakafi Program Enrollment Form

Patient Authorization for the IncyteCARES for Jakafi Program - Online

IncyteCARES for Jakafi Program Enrollment Form - Online

IncyteCARES for Jakafi Temporary Access Program - 30 Day Supply

Learn More

Overview

Provide patient immediate access to therapy during an insurance delay (typically new starts; some may cover change in insurance)
Limited time/ fill (typically 7-30 days; some may offer additional fill for continued delay up to certain limit)

Patient benefit

100% free (outside of insurance)

Patient eligibility

HCP must enroll patient
May be limited to commercially insured patients (i.e., no government beneficiaries); some programs may allow government beneficiaries

How to sign up

Typically HCP assisted enrollment (via form)

Foundation programs

under insured

no insurance

goverment insurance

65+

IncyteCARES for Jakafi Program Enrollment Form

Patient Authorization for the IncyteCARES for Jakafi Program - Online

IncyteCARES for Jakafi Program Enrollment Form - Online

IncyteCARES for Jakafi Patient Assistance Program (PAP)

Learn More

Overview

Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned

Patient benefit

Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted

Patient eligibility

Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.

How to sign up

Patients submit proof of out-of-pocket drug costs to charities for reimbursement

patient education

Jakafi Patient education

Getting started on Jakafi

NOT PROVIDED BY BRANDInstructions For Use: Polycythemia Vera (PV)

NOT PROVIDED BY BRANDInstructions For Use: Myelofibrosis (MF)

NOT PROVIDED BY BRANDInstructions For Use: Acute GVHD

NOT PROVIDED BY BRANDInstructions For Use: Chronic GVHD